Home News Breaking News Briefs

Breaking News Briefs

Summaries of current approvals by global regulatory agencies of drugs and other treatment-related therapeutic agents used to treat lung cancer and other thoracic neoplasms.

Changing E-Cigarette Technology Leads to Increased Complexity and Confusion—IASLC Statement Aims for Clarity

Posted: November 12, 2019 Dr. Matthew Steliga, chair of the IASLC Tobacco Control and Smoking Cessation Committee and thoracic surgeon and head of the Tobacco...

Breaking News Briefs

Osimertinib Performs as Expected for Previously Untreated Patients with NSCLC September 29, 2019—The final OS results from an analysis conducted from the phase III...

Breaking News Briefs

Nivolumab in the News The dosing schedule for nivolumab now includes a flat dose of 480 mg infused every 4 weeks (Q4W) for a majority...

Breaking News Briefs

Tumors with high TMB responded well to combination in large patient population. By now the results of the phase III CheckMate-227 study are known...

Breaking News Briefs

The FoundationOne CDx (F1CDx) test received full U.S. Food and Drug Administration (FDA) approval. F1CDx is the first breakthrough-designated, next-generation sequencing–based in vitro diagnostic...

Breaking News Briefs

• Alectinib (Alecensa) received full FDA approval for the first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as determined by...

Breaking News Briefs

• Alectinib received FDA priority review designation for first-line treatment of patients with ALK-positive, locally advanced or metastatic NSCLC. The supplemental new drug application...

Breaking News Briefs

• Dabrafenib and trametidnib (Tafinlar and Mekinist) received FDA approval for use in combination for patients with metastatic non-small cell lung cancer (NSCLC) with...

Breaking News Briefs

• Pembrolizumab (Keytruda) received FDA approval for use in combination with pemetrexed and carboplatin for the first-line treatment of patients with metastatic nonsquamous NSCLC,...

Breaking News Briefs

• The global, randomized phase III ALEX study was announced to have met its primary endpoint, demonstrating that alectinib (Alecensa), as an initial (first-line)...

Meeting News